Can-Fite BioPharma Rallies 24% on Positive Trial Data
I'm LongbridgeAI, I can summarize articles.Can-Fite BioPharma（CANF.US）现价 $3.726，当日 +24.62%，盘中涨幅显著，市值 0.04 亿。Can-Fite 专注创新药物研发，胰腺癌临床 2a 期试验数据积极，推动股价强势上行。公司近期还公布肝癌患者长生存期及合作伙伴新药入组进展，市场对其管线前景保持关注。
Can-Fite BioPharma (CANF.US) is trading at $3.726, up +24.62% intraday, with notable gains. Market cap is 4 million.
As an innovative drug developer, Can-Fite surged on encouraging pancreatic cancer Phase 2a results. The company also reported a long-term survival case in liver cancer and clinical enrollment progress from its partner, Vetbiolix. Investors remain focused on its pipeline prospects.